Efficacy of First Line Systemic Chemotherapy and Multikinase Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis
BackgroundHepatocellular carcinoma (HCC) is the third most fatal cancer, with a 5-year survival rate of 18%. Standard frontline-therapy is multikinase inhibitors (MKIs), but accessibility is still limited, particularly in developing countries. This network meta-analysis (NMA) aimed to compare the ef...
Main Authors: | Songporn Oranratnachai, Sasivimol Rattanasiri, Anantaporn Pooprasert, Amarit Tansawet, Thanyanan Reungwetwattana, John Attia, Ammarin Thakkinstian |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-03-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.654020/full |
Similar Items
-
Predicting HCC Response to Multikinase Inhibitors With In Vivo Cirrhotic Mouse Model for Personalized TherapySummary
by: Daniel Q. Huang, et al.
Published: (2021-01-01) -
Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study
by: Changhoon Yoo, et al.
Published: (2021-03-01) -
Lupus-Like Glomerulonephritis Associated With Regorafenib, a Multikinase Inhibitor
by: Anna Strasma, et al.
Published: (2021-03-01) -
Rare complications of multikinase inhibitor treatment
by: Fabián Pitoia, et al. -
Side skin reactions of multikinase inhibitors in treatment of thyroid cancer
by: F. S. Sevryukov, et al.
Published: (2021-01-01)